INT186163

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2004
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 4.23
Pain Relevance 1.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

RNA binding (NOVA2) nucleus (NOVA2)
Anatomy Link Frequency
lateral 2
neurite 2
interneurons 2
NOVA2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 53 96.20 Very High Very High Very High
cytokine 21 95.28 Very High Very High Very High
Spinal cord 72 87.92 High High
fluoxetine 18 85.52 High High
Bile 1 81.76 Quite High
Dopamine 50 78.56 Quite High
Hippocampus 14 73.16 Quite High
Hyperalgesia 5 70.72 Quite High
allodynia 14 69.36 Quite High
amygdala 44 67.00 Quite High
Disease Link Frequency Relevance Heat
Necrosis 112 100.00 Very High Very High Very High
Stress 82 99.12 Very High Very High Very High
Injury 147 97.72 Very High Very High Very High
Toxicity 53 97.30 Very High Very High Very High
Hepatotoxicity 17 96.92 Very High Very High Very High
INFLAMMATION 69 96.20 Very High Very High Very High
Anxiety Disorder 28 94.24 High High
Aging 23 93.88 High High
Cancer 19 80.32 Quite High
Apoptosis 30 79.20 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Post hoc tests are routinely applied in such situations, whether the overall ANOVA was significant or not.
Spec (whether) Positive_regulation (overall) of Spec (whether) Gene_expression (overall) of ANOVA
1) Confidence 0.34 Published 2008 Journal BMC Physiol Section Body Doc Link PMC2496911 Disease Relevance 0 Pain Relevance 0.31
Significant increases in both participant cortisol-levels (repeated-measures ANOVA, pre?
Positive_regulation (increases) of Gene_expression (measures) of ANOVA
2) Confidence 0.23 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2713432 Disease Relevance 0.47 Pain Relevance 0.06
The interactions between age classes and testing events were not significant (Two-way RM-ANOVA LIO: F8, 636?
Positive_regulation (-) of Gene_expression (way) of ANOVA
3) Confidence 0.22 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2779852 Disease Relevance 0 Pain Relevance 0
17.31, p<0.001; Fig. 2a and 2b) and the age classes (Two-way RM-ANOVA: LIO: F2, 159?
Positive_regulation (-) of Gene_expression (17.31) of ANOVA
4) Confidence 0.22 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2779852 Disease Relevance 0 Pain Relevance 0
g/ml produced a modest neurite toxicity, this was not robustly observed when subsequent experiments were performed (the effect was not significant when all data was analysed using ANOVA with a Bonferroni post-hoc test, although a direct comparison of control versus Cisplatin 1 ?
Positive_regulation (versus) of Gene_expression (using) of ANOVA in neurite associated with toxicity
5) Confidence 0.10 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1950519 Disease Relevance 0.74 Pain Relevance 0
RIA assays (Figure 1D) demonstrated large increases in pYE27 (mixed design ANOVA, Treatment × Side interaction: F3,15?
Positive_regulation (increases) of Gene_expression (mixed) of ANOVA
6) Confidence 0.06 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2978093 Disease Relevance 0.05 Pain Relevance 0.10
When the ANOVA produced significant results, we then performed the post hoc Fisher’s protected least-significant difference test for comparisons between groups.
Positive_regulation (When) of Gene_expression (produced) of ANOVA
7) Confidence 0.04 Published 2004 Journal Environ Health Perspect Section Body Doc Link PMC1247475 Disease Relevance 0.34 Pain Relevance 0.03
IL-6 deficiency attenuated the age-related loss of PV-interneurons (Fig. 4c); two-way ANOVA analysis of the genotype×age interaction showed a statistically significant effect for area CA3 (F(1,23)?
Positive_regulation (way) of Gene_expression (analysis) of ANOVA in interneurons
8) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2678193 Disease Relevance 0.21 Pain Relevance 0.15
Estimated fiber length was not significantly different (One-way ANOVA: F?
Neg (not) Positive_regulation (different) of Neg (not) Gene_expression (different) of One-way ANOVA
9) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2690693 Disease Relevance 0.40 Pain Relevance 0.03
8) had a significant increase in percentage of REM sleep (two-way ANOVA, for treatment×day/night, F2, 42?
Positive_regulation (way) of Gene_expression (sleep) of ANOVA
10) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2709920 Disease Relevance 0 Pain Relevance 0
The western blots for NR2A indicated no significant change in the expression of protein (ANOVA on raw data, p > 0.05) (Figure 7).
Neg (no) Positive_regulation (change) of Gene_expression (expression) of ANOVA
11) Confidence 0.03 Published 2005 Journal Mol Pain Section Body Doc Link PMC1208948 Disease Relevance 0.39 Pain Relevance 0.50
To identify the genes that are significantly differentially expressed among the different levels of necrosis, an unbalanced one-way ANOVA was fitted for each gene,
Positive_regulation (fitted) of Gene_expression (expressed) of ANOVA associated with necrosis
12) Confidence 0.03 Published 2008 Journal BMC Genomics Section Body Doc Link PMC2478688 Disease Relevance 1.25 Pain Relevance 0.09
ANOVA: analysis of variance; BSA: bovine serum albumin; IVN: inferior vestibular nucleus; LVN: lateral vestibular nucleus; MVN: medial vestibular nucleus; NF?
Positive_regulation (variance) of Gene_expression (analysis) of ANOVA in lateral
13) Confidence 0.03 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC3004876 Disease Relevance 0.38 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox